BeOne Medicine's HER2 bispecific antibody combo succeeds in phase 3 trial

Zanidatamab is a humanized HER2-targeted bispecific antibody uniquely engineered to bind two non-overlapping extracellular domains of HER2. This bispecific design promotes enhanced receptor internalization and downregulation on tumor cells, leading to potent antitumor activity. Mechanistically, it induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP)—synergistic effects that have demonstrated significant tumor growth inhibition and cell death in preclinical models.

As a cornerstone of BeOne Medicine's solid tumor portfolio, tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody designed to minimize Fcγ receptor binding on macrophages. This design helps prevent Fc-mediated T-cell clearance, thereby preserving immune effector function and enhancing antitumor immunity.

The combination of zanidatamab and tislelizumab represents a strategic integration of targeted therapy and immuno-oncology. This approach not only maintains the precision of HER2 blockade but also introduces the potential for durable immune-mediated benefits. By concurrently targeting HER2 signaling and reactivating antitumor immunity, the regimen offers both immediate tumor control and the potential for long-term immunologic memory, supporting sustained therapeutic efficacy.

Study Design and Clinical Results

The HERIZON-GEA-01 trial is a global, randomized, open-label Phase 3 study enrolling patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). Patients were randomized into three treatment arms: zanidatamab combined with tislelizumab and chemotherapy, zanidatamab plus chemotherapy, and the control arm receiving standard-of-care trastuzumab plus chemotherapy.

Results demonstrated that compared to the control arm, zanidatamab combined with tislelizumab and chemotherapy showed clinically meaningful and highly statistically significant improvements in both progression-free survival (PFS) and overall survival (OS). Zanidatamab plus chemotherapy also demonstrated clinically meaningful and statistically significant improvement in PFS, along with a clinically meaningful trend toward OS benefit at the first interim analysis.

Notably, PFS and OS benefits were observed with both investigational arms versus the control arm across both PD-L1 positive and PD-L1 negative subgroups, indicating that treatment efficacy was broadly consistent regardless of PD-L1 expression status. Additionally, both combination arms showed improvements in key secondary endpoints including objective response rate (ORR) and duration of response (DOR).

The safety profiles of zanidatamab in combination with tislelizumab and chemotherapy, as well as zanidatamab with chemotherapy alone, were generally consistent with the known safety profile of each individual agent. No new safety signals were identified, supporting a favorable benefit-risk profile for zanidatamab in this indication.

Unmet Needs in Gastroesophageal Adenocarcinoma

Gastroesophageal adenocarcinoma (GEA) ranks as the fifth most common cancer globally, with approximately 20% of cases being HER2-positive. This aggressive cancer is associated with high morbidity and mortality, and patient outcomes remain poor—the global five-year survival rate stands below 30% for gastric cancer and around 19% for GEA. Most patients are diagnosed at an advanced stage, where treatment options are limited, creating a pressing need for new therapeutic strategies.

The current first-line standard of care for HER2-positive GEA remains trastuzumab combined with chemotherapy, yet treatment efficacy remains suboptimal, with median overall survival generally unsatisfactory. As the disease progresses, later-line options become even more limited, underscoring the important clinical implications of the positive results from the HERIZON-GEA-01 trial.

Market Competition Landscape and Product Positioning

In the global HER2-targeted therapy landscape, key approved products include trastuzumab, pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd). However, treatment options remain relatively limited for HER2-positive gastroesophageal adenocarcinoma (GEA), leaving significant market potential for innovative therapeutic approaches.

As a bispecific antibody, zanidatamab differs mechanistically from conventional monoclonal antibodies by simultaneously binding two distinct epitopes on HER2. This unique binding promotes stronger receptor clustering and internalization, potentially leading to enhanced antitumor activity. Compared to antibody-drug conjugates (ADCs), bispecific antibodies do not carry cytotoxic payloads, which may offer a more favorable safety profile.

BeOne Medicine's commercial strategy aims to establish the combination of zanidatamab and tislelizumab as a new first-line standard for HER2-positive GEA. The company has previously secured approvals for zanidatamab in HER2-high expressing biliary tract cancer in China, as well as in the U.S. and EU for eligible biliary tract cancer patients, providing valuable experience for its expansion into the GEA field.

From a competitive perspective, this combination therapy offers a differentiated advantage by simultaneously targeting the HER2 signaling pathway and the PD-1 immune checkpoint, potentially delivering synergistic efficacy for patients. If ultimately approved, it is well-positioned to set a new treatment standard in the HER2-positive GEA therapeutic landscape.